ABL Bio Inc
298380
Company Profile
Business description
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
Contact
2nd Floor, 16 Daewangpangyo-Ro 712
Beon-Gil, Bundang-Gu
Gyeonggi-do
Seongnam-si13488
KORT: +82 3180189800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
105
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,391.20 | 17.50 | 0.19% |
| CAC 40 | 8,206.07 | 31.87 | 0.39% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 26,347.37 | 488.54 | 1.89% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,929.81 | 744.31 | 1.51% |
| NZX 50 Index | 13,356.12 | 11.16 | 0.08% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,094.10 | 18.20 | 0.20% |
| SSE Composite Index | 3,899.64 | 35.75 | 0.93% |